

in 2020  
**37.6**  
million  
people

globally were living  
with HIV,  
including  
1.7 million children



**HIV**

**34.7**  
million  
people

have died  
from AIDS-related illnesses  
since the start of  
the epidemic



**27.4 million**  
people

were accessing antiretroviral therapy in 2020,  
an increase of

**2 m since 2019**



**26%**  
of adults



**47%**  
of children

living with HIV still miss out on HIV treatment,  
of whom the vast majority lives in low- and  
middle-income countries<sup>2</sup>


<sup>2</sup> UNAIDS, 2020 fact sheet (last accessed on 14 June 2021)




## MPP's WORK IN HIV

Note that supplies of MPP-licensed products may occur outside of the licence(s) covered territory but where no patents are infringed, and/or in countries in the absence of registration via procurement channels, registration waivers and/or exemptions.


### 01 dolutegravir (DTG) adult 50 mg




### 02 tenofovir disoproxil fumarate/lamivudine/dolutegravir (TDF/3TC/DTG – also known as TLD) 300/300/50 mg




### 03 tenofovir alafenamide/emtricitabine/dolutegravir (TAF/FTC/DTG) 25/200/50 mg



### 04 atazanavir/ritonavir (ATV/r) 300/100 mg




05 lopinavir/ritonavir (LPV/r) 100/25 mg & 200/50 mg



Data as of 31 December 2020, provided by MPP's sublicensees

In March 2020, AbbVie issued a worldwide commitment not to enforce patents on lopinavir and ritonavir product, thus enabling supplies from MPP's sublicensees outside of the MPP licence territory.

06 lopinavir/ritonavir (LPV/r) paediatric 40/10 mg



Data as of 31 December 2020, provided by MPP's sublicensees

In March 2020, AbbVie issued a worldwide commitment not to enforce patents on lopinavir and ritonavir product, thus enabling supplies from MPP's sublicensees outside of the MPP licence territory.

\*For confidentiality purposes, countries will be disclosed when approval from a stringent regulatory authority (SRA) for this product has been granted to more than one sublicensee.



Dolutegravir either on its own or in combination (TLD) has been supplied in

**113 countries**



**> 27.3 million**


patient-years of treatments have been supplied between 2017-2020



**34% & 12%**

decline in average price of DTG and TLD respectively between 2017-2020

**CUMULATIVE PACKS (30'S) OF DTG AND TLD SOLD BY MPP LICENSEES**



**TOP 10 COUNTRIES**

**SUPPLIED IN 2020 WITH DTG AND/OR TLD COMBINATIONS THROUGH OUR LICENSEES**

	Packs of 30's		Estimated number of people living with HIV (Source UNAIDS)
	DTG 50mg	TLD	
Botswana	21,120	5,530,492	380,000
Ethiopia	1,015,544	4,906,285	670,000
Kenya	1,952,176	11,110,778	1,500,000
Malawi	603,693	13,593,432	1,100,000
Mozambique	451,208	11,099,983	2,200,000
Nigeria	877,683	9,041,824	1,800,000
South Africa	1,462,582	28,075,902	7,500,000
Tanzania	537,345	15,884,050	1,700,000
Uganda	457,665	12,024,169	1,500,000
Zimbabwe	0	7,481,418	1,400,000

**NEW COUNTRIES SUPPLIED IN 2020**

	Packs of 30's		Estimated number of people living with HIV (Source UNAIDS)
	DTG 50mg	TLD	
Angola	51,288	558,213	340,000
Chad	-	66,216	120,000
Ecuador	11,459	6,096	47,000
Eritrea	252	119,800	14,000
Gambia (the)	9,066	94,316	28,000
Indonesia	150,000	419,824	640,000
Niger	14,121	62,952	33,000
Panama	10,130	99,583	26,000
Philippines	5,250	197,260	97,000
Thailand	102,261	61,580	470,000

globally, an estimated

**58**  
million  
people

have chronic hepatitis C infection with an important proportion developing cirrhosis or liver cancer

direct-acting antiviral medicines (DAAs) can cure

**>95%**  
of patients

But still, access to diagnosis and treatment is low, especially in low- and middle-income countries, where the vast majority of people with the virus live.



# Hepatitis C

Access to hepatitis C treatment is improving but remains too limited.

In 2019, **21%**

of those living with the HCV infection knew their diagnosis.

Of those diagnosed with chronic HCV infection, 9.4 million people (62%) had been treated with DAAs by the end of 2019.

Much more needs to be done to achieve

**80%**

HCV treatment target by 2030<sup>3</sup>.


<sup>3</sup> World Health Organization, Global report on HIV, viral hepatitis and sexually transmitted infections, 2021




## MPP'S WORK IN HEPATITIS C

Note that supplies of MPP-licensed products may occur outside of the licence(s) covered territory but where no patents are infringed, and/or in countries in the absence of registration via procurement channels, registration waivers and/or exemptions.

### 01 daclatasvir (DAC) 30 mg and 60 mg




### 02 daclatasvir + sofosbuvir (DAC + SOF) 60/400 mg






## MPP's WORK IN HEPATITIS C



### VOLUMES VS PRICE OF GENERIC DACLATASVIR SALES



\* 1 HCV treatment = 12 weeks therapy (3packs)

Data as of December 2020

### TOP 10 COUNTRIES SUPPLIED IN 2020 WITH DAC AND/OR DAC COMBINATIONS

	Treatments supplied (DAC AND/OR DAC/SOF)	Estimated HCV Disease Burden (Source Polaris <sup>4</sup> )
India	865,452	6,076,000
Indonesia	15,284	1,360,000
Kazakhstan	36,777	374,000
Malaysia	10,703	386,000
Myanmar	25,431	376,000
Pakistan	78,565	6,840,000
Rwanda	43,999	97,400
Ukraine	22,605	1,352,000
Uzbekistan	12,633	1,005,000
Viet Nam	26,669	1,009,000

### NEW COUNTRIES SUPPLIED IN 2020

	Treatments supplied (DAC AND/OR DAC/SOF)	Estimated HCV Disease Burden (Source Polaris <sup>4</sup> )
Argentina	504	317,000
Armenia	939	64,200
Cuba	1,224	55,500
Ethiopia	Under 500	641,000
Moldova	106	119,000
Philippines	Under 500	626,000
Tajikistan	100	252,000
Tanzania	886	467,000
Timor-Leste	Under 500	-
Turkmenistan	3,750	159,000

<sup>4</sup> <https://cdfound.org/polaris/>

TB is one of the  
**top 10**  
killers  
globally

& the leading cause  
of death for people living  
with HIV

in 2019

**10**  
million  
people


fell ill with TB, including  
1.2 million children

**1.4**  
million

died  
from the disease,  
including

**208,000**

people with HIV



# Tuberculosis

Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat. A global total of 206,030 people with multidrug- or rifampicin-resistant TB (MDR/RR-TB) were officially diagnosed and notified in 2019, a 10% increase from 2018. Ending the TB epidemic by 2030 is among the health targets of the Sustainable Development Goals (SDGs). To meet this target, faster-acting and better therapies to treat TB are urgently needed, particularly for MDR-TB<sup>5</sup>.

<sup>5</sup> World Health Organization, Fact Sheet, Tuberculosis, October 2020 (website accessed on 14 June 2021)